Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

    ... The hypomethylating agents (HMAs) azacitidine and decitabine have changed the treatment landscape of ...

    Research Article last updated 01/03/2013 - 9:48am.

  2. Combination strategies in myelodysplastic syndromes.

    ... Scoring System . Currently, lenalidomide , azacitidine , and decitabine are the only three FDA-approved drugs ...

    Research Article last updated 04/24/2012 - 2:18pm.

  3. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... Drug Administration-approved for treatment of MDS: (1) azacitidine , (2) decitabine , and (3) lenalidomide . ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... with higher-risk MDS include hypomethylating agents ( azacitidine and decitabine ), intensive chemotherapy (ICT), ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Myelodysplastic syndromes in older adults.

    ... the drugs lenalidomide , decitabine , and azacitidine have offered treatment options to patients ineligible for ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

    ... such as decitabine (5-aza-deoxycytidine) and 5- azacitidine , have led to the expansion of the therapeutic arsenal for MDS. ... and head-to-head comparison studies of decitabine and 5-azacitidine will provide valuable pre-clinical and clinical data, enhancing ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Current and future management options for myelodysplastic syndromes.

    ... of US FDA-approved agents such as lenalidomide , azacitidine and decitabine . Prior to these developments, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. An update on the treatment of myelodysplastic syndromes.

    ... with del(5q), and two different hypomethylating agents, azacitidine and decitabine , are approved for intermediate-2- and ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Pharmacotherapy of myelodysplastic syndromes.

    ... the past decade, response to the hypomethylating agents azacitidine and decitabine in non-del(5q) MDS patients remains at ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

    ... agents currently approved in the United States-- azacitidine or decitabine --to patients with aggressive forms of ...

    Research Article last updated 10/11/2011 - 5:58pm.